There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Atopic dermatitis (AD) is characterized by skin barrier defects, T helper type 2 cell
activation, and increased risk for cutaneous and extracutaneous infections. In clinical
trials, dupilumab appeared to decrease rates of skin infections in AD.
Title:
Journal of the American Academy of Dermatology
Publisher:
Elsevier BV
ISSN
(Electronic):
1097-6787
ISSN
(Print):
0190-9622
Publication date
(Electronic):
Jan 2018
Volume: 78
Issue: 1
Affiliations
[1
]
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario,
Canada.
[2
]
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario,
Canada; Division of Dermatology, Department of Medicine and Women's College Research
Institute, Women's College Hospital, Toronto, Ontario, Canada; Department of Dermatology,
Brown University, Providence, Rhode Island. Electronic address: aaron.drucker@wchospital.ca.